PT  - JOURNAL ARTICLE
AU  - Min Zhao
AU  - Fazhong He
AU  - Yang Yang
AU  - Weijie Lin
AU  - Wentao Qiu
AU  - Qian Meng
AU  - Jianping Zhang
AU  - Zhiling Zhou
TI  - Therapeutic efficacy of tacrolimus in vernal keratoconjunctivitis: a meta-analysis of randomised controlled trials
AID  - 10.1136/ejhpharm-2020-002447
DP  - 2022 May 01
TA  - European Journal of Hospital Pharmacy
PG  - 129--133
VI  - 29
IP  - 3
4099  - http://ejhp.bmj.com/content/29/3/129.short
4100  - http://ejhp.bmj.com/content/29/3/129.full
SO  - Eur J Hosp Pharm2022 May 01; 29
AB  - Background and objective Tacrolimus has been widely used in recent years for treating allergic conjunctivitis, but there is currently no available meta-analysis regarding its therapeutic efficacy. This study systematically evaluated the effectiveness of tacrolimus in the treatment of allergic conjunctivitis.Methods Data obtained from literature searches of the PubMed, Cochrane Library, Embase, CNKI, and Wanfang databases were retrieved by combining medical subject words and free words. Literature was selected on the basis of established inclusion and exclusion criteria, and the extracted data were evaluated for risk of bias using RevMan 5.3 for meta-analysis.Results A total of 177 articles were retrieved, of which 5 articles were eventually selected, all of which involved tacrolimus treatment for vernal keratoconjunctivitis. A total of 203 samples were analysed. Results of the meta-analysis showed that the tacrolimus treatment group had significantly lower ocular objective sign scores (SMD −1.39, 95% CI −2.50 to −0.27; p<0.05) and had a significantly lower subjective symptom evaluation score (SMD −0.92, 95% CI −1.59 to −0.24; p<0.05) than the control group.Conclusion Current evidence shows that tacrolimus is effective in treating vernal keratoconjunctivitis.Data is available in a public, open access repository. Data comes from PubMed, Cochrane Library, Embase, CNKI, and Wanfang databases.